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BACKGROUND & AIMS: The DNA/RNA editing enzyme activation-induced cytidine 
deaminase (AID) is mutagenic and has been implicated in human tumorigenesis. Helicobacter 
pylori (H.pylori) infection of gastric epithelial cells leads to aberrant expression of AID and 
somatic gene mutations. We investigated whether AID induces genetic aberrations at specific 
chromosomal loci that encode tumor-related proteins in gastric epithelial cells.  
METHODS: Human gastric epithelial cell lines that express activated AID and gastric cells 
from AID transgenic mice were examined for DNA copy-number changes and nucleotide 
alterations. Copy number aberrations in stomach cells of H. pylori-infected mice and gastric 
tissues (normal and tumor) from H. pylori-positive patients were also analyzed.  
RESULTS: In human gastric cells, aberrant AID activity induced copy number changes at 
various chromosomal loci. In AID-expressing cells and gastric mucosa of AID transgenic mice, 
point mutations and reductions in copy number were observed frequently in the tumor suppressor 
genes CDKN2A and CDKN2B. Oral infection of wild-type mice with H.pylori reduced the copy 
number of the Cdkn2b-Cdkn2a locus, whereas no such changes were observed in the gastric 
mucosa of H.pylori-infected AID-deficient mice. In human samples, the relative copy numbers 
of CDKN2A and CDKN2B were reduced in a subset of gastric cancer tissues, compared with the 
surrounding non-cancerous region.  
CONCLUSIONS: H.pylori infection leads to aberrant expression of AID and might be a 
mechanism of the accumulation of submicroscopic deletions and somatic mutations in gastric 
epithelial cells. AID-mediated genotoxic effects appear to occur frequently at the the 
CDKN2b-CDKN2a locus and contribute to malignant transformation of the gastric mucosa. 




Increasing evidence indicates that cancer arises from a stepwise accumulation of genetic 
changes and that the incipient cancer cells acquire mutant alleles of tumor-suppressor genes 
and/or proto-oncogenes 1. Genetic alterations observed in cancers include point mutations, 
chromosomal number alterations, chromosomal translocations, and gene deletions or 
amplifications 2. A number of human cancers have deletions and/or point mutations at specific 
gene loci, causing the putative inactivation of tumor-suppressor genes. Thus, elucidation of the 
molecular mechanisms underlying the genetic alterations that occur at the loci encoding 
tumor-suppressor proteins is important to gain a better understanding of tumorigenesis.  
A novel mechanism of genetic alterations, i.e., DNA/RNA editing by members of cytidine 
deaminases, was recently reported 3-5. Among the 11 human cytidine deaminases identified, 
activation-induced cytidine deaminase (AID) is the only molecule that exerts genetic effects on 
human DNA sequences under physiologic conditions. AID is an essential enzyme for somatic 
hypermutation, class switch recombination (CSR), and gene conversion, all of which are crucial 
steps to achieve the diversification of the immunoglobulin (Ig) genes in activated B lymphocytes 
3. In sharp contrast to the physiologic role of AID in the editing of the Ig genes, we recently 
demonstrated a pathologic role of AID linking the accumulation of nucleotide alterations in 
tumor-related genes and human cancer development 6-8. Indeed, aberrant expression of AID is 
induced in response to pro-inflammatory cytokine stimulation in gastric epithelial cells, colon 
epithelial cells, biliary ductal cells, and hepatocytes and leads to the accumulation of somatic 
mutations in various tumor-related genes in vitro 9-13. Moreover, we showed that infection with 
Helicobacter pylori (H.pylori), a class one carcinogen for gastric cancer, induces aberrant AID 
expression in gastric epithelial cells, resulting in the accumulation of TP53 tumor suppressor 
gene mutations 13. Consistent with these in vitro findings, a mouse model with continuous and 
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ubiquitous expression of AID develops cancers in several epithelial organs, including stomach, 
liver, and lung, via the accumulation of somatic mutations 14-16. These findings elucidated a 
novel molecular mechanism linking inflammation, genetic mutations, and cancer development. 
Because AID can trigger a CSR of the Ig gene, it is reasonable to assume that AID can also 
mediate chromosomal aberrations by triggering double-strand DNA breaks (DSBs) in lymphoid 
cells, in addition to somatic point mutations. Indeed, recent studies revealed that AID is required 
for the generation or accumulation of chromosomal translocations during lymphoma 
development 17. For example, translocations between c-myc and the IgH locus (Igh) are induced 
in primary B cells within hours of AID expression, while c-myc-Igh translocations are absent in 
AID-deficient mice 18-23. These findings prompted us to speculate that aberrant expression of 
AID in epithelial cells might cause not only somatic point mutations but also chromosomal 
alterations, both of which would play critical roles in the activation and/or inactivation of 
tumor-related genes. In this study, therefore, we investigated whether the genotoxic activity of 
AID could underlie the emergence of genetic aberrations at specific chromosomal loci encoding 
tumor-related proteins in human gastric epithelial cells and thus contribute to the development of 
gastric cancers. 
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Materials and Methods 
Mice 
The generation of transgenic (Tg) mice with constitutive and ubiquitous AID expression and 
AID-deficient mice was described previously 15, 24. Wild-type (WT) C57BL/6J mice were 
purchased from Japan SLC, INC. (Shizuoka, Japan). For infection, mice were challenged with 
1.5 x 107 cfu CagPAI-positive (TN2GF4) H.pylori as described previously25-27. All experiments 
involving mice conform to the relevant regulatory standards and were reviewed and approved by 
Kyoto University School of Medicine Institutional Animal Care and Use Committee. 
Cell culture and transfection 
AGS human gastric epithelial cells and stable transfection of AID-expressing vector into AGS 
cells was described previously 13. 
Genomic PCR, RT-PCR, and quantitative real-time genomic and RT-PCR 
The oligonucleotide primers used are shown in Supplementary Table 1. Quantification of gene 
expression or gene copy numbers was performed by quantitative real-time RT-PCR or genomic 
PCR using a Light Cycler 480 and Fast Start Universal Probe or SYBR Master (Roche, 
Mannheim, Germany)9. To assess the quantity of isolated DNA, target DNAs were normalized to 
the DNA levels of the housekeeping reference gene human ACTB or mouse Actb. For simplicity, 
the ratios are represented as relative values, target gene/human ACTB or mouse Actb. 
Comparative genomic hybridization (CGH) microarray analysis 
Genomic analyses were performed on Human 44K Agilent arrays CGH (Agilent Technologies, 
Santa Clara, CA) according to the manufacturer's protocol. DNA extracted from 
AID-overexpressing AGS cells and reference DNA were both labeled by random priming with 
Cy3-dCTP and Cy5-dCTP for dye-swap experimental design. Arrays were scanned on an 
Agilent microarray scanner. Data were extracted and flagged with the Feature Extraction 
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software. Agilent CGH Analytics software was used to identify regions of copy number 
alteration. 
Fluorescence in situ hybridization (FISH) analysis 
DNA probes specific to CDKN2b–CDKN2a locus and ELAVL2 gene were amplified using the 
primers shown in Supplementary Table 1. These probes were labeled by nick-translation with 
either SpectrumGreen- or SpectrumOrange-labeled dUTP and hybridized to chromosomes of 
AGS cells expressing AID for 21 days. Images were taken with the fluorescence microscope 
MD5000B (Leica, Wetzlar, Germany). 
DNA polymorphism analysis 
The DNA polymorphism analyses of restriction fragment length polymorphisms were performed 
to detect loss of heterozygosity (LOH). PCR was performed using the primer sets shown in 
Supplementary Table 1, and PCR products were digested with Dde I (for human CDKN2A) or 
Psp 1406 I (for human CDKN2B). 
Southern blot analysis 
Southern blot analysis of the PCR products was performed using AlkPhos Direct Labelling 
Reagents (GE Healthcare, Buckinghamshire, UK), with DNA probes labeled using alkaline 
phosphatase, according to the manufacturer's protocol. The primer sets used are shown in 
Supplementary Table 1. 
Subcloning and sequencing of tumor-related genes 
The oligonucleotide primers used are shown in Supplementary Table 1. Amplification of the 
target sequences was performed using high-fidelity Phusion Taq polymerase (Finnzymes, Espoo, 
Finland), and the products were subcloned into a pcDNA3 vector (Invitrogen, Carlsbad, CA). 
The resulting plasmids were subjected to sequence analysis 11. 
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Patients 
The study group comprised 28 patients who had undergone potentially curative resection of 
primary gastric cancer at Kyoto University Hospital from 2006 to 2007. Written informed 
consent for the use of the resected tissues was obtained from all patients in accordance with the 
Declaration of Helsinki, and the Kyoto University Graduate School and Faculty of Medicine 
Ethics Committee approved the study. 
Statistics 
Statistical significance (P < 0.05) was evaluated using the χ2 test for sequence and FISH analyses, 





AID expression induces chromosomal aberrations in gastric epithelial cells. 
To view the overall landscape of the genetic alterations caused by AID activation in 
human gastric epithelial cells, we used a system that allows for conditional AID activation by 
constructing a stable transfectant of AID fused with the hormone-binding domain of the human 
estrogen receptor in the human gastric epithelial cell line AGS (Supplementary Figure 1). We 
then conditionally activated AID in the cells by introducing an estrogen analogue, 4- 
hydroxytamoxifen13, 28, followed by CGH analyses performed on DNA samples extracted from 
the cells with or without AID activation. Copy number changes emerged in a number of 
submicroscopic areas in almost all chromosomes of the cells with AID activation compared with 
the control cells (Supplementary Figure 2). Most of the changes observed in the AID-expressing 
cells were submicroscopic deletions represented by copy number losses of various chromosomal 
loci, whereas large-scale deletions or changes in chromosomal number, such as monosomy, were 
not apparent in the cells with AID expression. In contrast, a submicroscopic copy number gain 
was observed in a few chromosomal loci on 3p, 10q, and 19p in AID-expressing cells 
(Supplementary Figure 2). Analysis of the time-course changes in the copy numbers revealed 
that the number of submicroscopic chromosomal deletions increased depending on the duration 
of AID activation in gastric cells (Figure 1A and Supplementary Table 2). These findings 
suggested that AID expression caused the copy number changes, mainly by inducing 
submicroscopic chromosomal deletions, in gastric epithelial cells. 
 
AID induces reductions of the CDKN2A and CDKN2B copy numbers in gastric epithelial 
cells. 
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Repeated CGH analyses on AGS cells showed that deletions at two specific loci, 9p21 
and 3q27, commonly occurred after 1-week and 3-week AID activation, though there were many 
deleted regions observed. Notably, these chromosomal regions harbored the tumor-suppressor 
genes cyclin-dependent kinase inhibitor 2A (CDKN2A) and cyclin-dependent kinase inhibitor 2B 
(CDKN2B) at 9p21, and B-cell CLL/lymphoma 6 (BCL6) at 3q27 (Figure 1A). It has been well 
recognized that CDKN2A and CDKN2B play crucial roles as tumor-suppressor genes in the 
development of various human tumors 29. Therefore, we further examined whether AID 
expression caused the deletion of the CDKN2b-CDKN2a locus at 9p21 using fluorescence in situ 
hybridization (FISH) analyses with the probes specific for CDKN2b-CDKN2a locus and control 
ELAVL2 gene. We found that significantly more deletions of CDKA2b-CDKN2a locus were 
present in human gastric cells with AID activation than those in the control cells (27.6% and 
6.9%, respectively; P < 0.001; Figure 1B and Table 1). In contrast, there was no significant 
difference in the frequency of deleted signals for ELAVL2 gene between AID-expressing cells 
and cells without AID activation (11.9% and 11.2%, respectively; Table 1). These results suggest 
that AID preferentially induces submicroscopic deletions of CDKN2A and CDKN2B genes in 
gastric epithelial cells. 
Next, we analyzed the gastric mucosa of AID Tg mice, which develop various tumors, 
including gastric cancer, in association with the accumulation of somatic mutations 16. We 
examined the relative copy number ratio of Cdkn2a and Cdkn2b at chromosome 4, and Bcl6 at 
chromosome 16, in non-cancerous gastric mucosa (NC) as well as in the gastric cancer tissue 
(GC) of AID Tg mice (Figure 2A). As a reference, we selected several genes, such as Acot7 at 
chromosome 4 and Actb at chromosome 5, that were located at stable chromosomal sites in the 
AID-expressing cells in vitro. The relative copy number ratios of Cdkn2a and Cdkn2b were 
significantly lower in gastric epithelial cells of AID Tg mice compared with those of the WT 
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mouse (P < 0.05; Figure 2B and C). Moreover, the gastric cancer tissues had substantially 
reduced amounts of Cdkn2a and Cdkn2b compared with the non-cancerous gastric mucosa in the 
AID Tg mice (Figure 2B and C). All of the AID Tg mice also had significantly reduced copy 
number levels of Bcl6 in the gastric mucosa compared with the WT mouse (P < 0.01; Figure 2D). 
In contrast, there was little difference in the copy numbers of the Acot7 gene between the gastric 
mucosa of the WT and AID Tg mice (Figure 2E). Southern blotting analyses revealed that 
signals derived from the Cdkn2a gene in the gastric mucosa of the AID Tg mice were 
substantially reduced compared with that in the WT mouse (Figure 2F). These findings together 
suggested that constitutive expression of AID in normal gastric epithelial cells resulted in 
submicroscopic Cdkn2a and Cdkn2b gene defects at high frequency in vivo. 
 
AID expression in gastric epithelial cells caused somatic mutations in the CDKN2A and 
CDKN2B genes. 
To further determine if the CDKN2A and CDKN2B genes are preferential targets of 
AID-mediated genotoxic effects, we examined whether somatic mutations are induced by AID 
activation in CDKN2A and CDKN2B genes of gastric cells in vitro and in vivo. In vitro, control 
AGS cells without AID activation contained only a single or two nucleotide alterations of the 
CDKN2A or CDKN2B gene sequences (Table 2). In contrast, gastric cells with AID activation 
had significantly higher frequencies of nucleotide alterations in the CDKN2A and CDKN2B 
genes than those in control cells (P < 0.01; Table 2). Of the 19 mutations in CDKN2A of 
AID-activated AGS cells, 1 was a nonsynonymous mutation and another was a frameshift 
mutation resulting in loss of function. Three of 11 mutations in CDKN2B of AID-activated AGS 
cells were nonsynonymous mutations. Substantially higher mutation frequency was also 
observed in the BCL6 gene in the cells with AID activation than that in control cells (Table 2). 
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Similar findings were obtained by analyses of the gastric mucosa from AID Tg mice. 
We detected only a single or two nucleotide alterations in either of the Cdkn2a or Cdkn2b genes 
in the gastric mucosa of WT mice (Table 3). In contrast, a number of somatic mutations were 
induced in the Cdkn2a and Cdkn2b genes in the gastric mucosa of AID Tg mice (Table 3). 
Significantly higher frequencies of nucleotide alterations in Cdkn2a and Cdkn2b genes were 
detected in non-cancerous tissue as well as in gastric cancer in AID Tg mice than in control 
gastric tissue from WT mice (P < 0.01; Table 3). Interestingly, 6 of 11 (55%) nucleotide changes 
in non-cancerous tissue and 10 of 14 (71%) in cancer tissue occurring in the coding sequences of 
the Cdkn2a gene were nonsynonymous mutations resulting in amino acid substitutions, and 1 of 
11 (9%) nucleotide alteration in non-cancerous tissue was a nonsense mutation resulting in a stop 
codon. Furthermore, 2 of 10 (20%) nucleotide changes in non-cancerous tissue and 1 of 14 (7%) 
in cancer tissue in the coding sequences of the Cdkn2b gene were also nonsynonymous 
mutations. In contrast, there was no difference in the mutation frequencies of the Bcl6 gene 
between AID Tg and WT mice. 
Taken together, these findings suggested that AID-triggered genotoxic effects were 
preferentially aimed at the CDKN2A and CDKN2B genes, and induced both submicroscopic 
deletions and nucleotide alterations of these tumor-suppressor genes in gastric epithelial cells. 
 
H. pylori infection triggered the loss of the Cdkn2a and Cdkn2b genes in gastric epithelial 
cells. 
We previously demonstrated that H.pylori infection induces aberrant expression of 
endogenous AID in gastric epithelial cells 13. To determine whether persistent H.pylori infection 
leads to changes in the Cdkn2a /Cdkn2b gene loci via AID expression, we orally infected WT 
C57BL/6J mice or AID-deficient mice with a cagPAI-positive pathogenic strain of H.pylori, 
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TN2GF4 (Supplementary Figure 3), and determined the relative copy number ratios of the 
Cdkn2a and Cdkn2b genes in the gastric mucosa. We first confirmed that oral infection of 
H.pylori in WT mice upregulated AID expression in the gastric mucosa (Figure 3A, upper panel), 
whereas endogenous AID expression was undetectable in uninfected mouse stomach (Figure 3A, 
upper panel) or in AID-deficient mice with H.pylori infection (Figure 3D, upper panel). 
Interestingly, relative copy number ratios of Cdkn2a were significantly lower in most of the 
stomachs of WT mice infected with H.pylori, compared with uninfected mice (P < 0.05; Figure 
3B). Similarly, there was a significant reduction in the copy number ratio of the Cdkn2b gene in 
the gastric mucosa in association with H.pylori infection, compared with the mice without 
H.pylori infection (P < 0.05; Figure 3C). In contrast, there was no change in the relative copy 
number ratio of the Cdkn2a and Cdkn2b genes in the stomach of AID-deficient mice with 
H.pylori infection (Figure 3E and F). These observations suggested that H.pylori infection 
triggered the submicroscopic deletion of Cdkn2a and Cdkn2b genes via endogenous AID 
expression in the gastric mucosa. 
Although the CGH array analyses on the gastric mucosa of the H.pylori-infected mouse 
detected a number of submicroscopic deletions in various chromosomal loci (Supplementary 
Figure 4), we did not detect a reduction in the copy number of the known tumor-related genes 
that are commonly reduced in the H.pylori-infected mouse stomach and the cultured human 
gastric cells with AID expression. 
 
Genetic alterations of CDKN2A and CDKN2B in H. pylori-positive human gastric cancers. 
Previous studies revealed that epigenetic changes in the promoter region contribute to 
the downregulation of CDKN2A or CDKN2B gene expression, leading to inactivation of these 
tumor-suppressor genes in various human cancers 30-33. In contrast, little is known about the 
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genetic alterations in CDKN2A and CDKN2B genes during human gastric cancer development. 
Thus, we analyzed the relative copy number ratios of CDKN2A and CDKN2B in 
H.pylori-positive human gastric cancer clinical specimens. The relative copy number ratio of the 
CDKN2A or CDKN2B genes was reduced to less than half in 10 of 28 (36%) tumors compared 
with those of the surrounding non-tumorous gastric mucosa of patients with gastric cancers, and 
the copy number of the CDKN2A or CDKN2B genes was significantly lower in tumorous tissue 
than in surrounding non-tumorous gastric mucosa among these cases (P < 0.05; Figure 4A and B). 
Real-time RT-PCR analyses revealed that the expression levels of both CDKN2A and CDKN2B 
transcripts were significantly lower in tumorous tissues than in non-tumorous gastric mucosa in 
the clinical specimens with CDKN2A and CDKN2B gene copy number reductions ( P < 0.05 ; 
Supplementary Figure 5A and B). Southern blot analyses revealed that genetic signals derived 
from the CDKN2A gene in cancer tissues were substantially smaller than those in the 
surrounding non-cancerous gastric mucosa of the 10 patients with the reduced levels of CDKN2A 
and CDKN2B copy numbers (Figure 4C, upper panel). In addition, DNA polymorphism analyses 
showed that LOH in CDKN2A or CDKN2B gene was detectable in 4 of 10 gastric cancer tissue 
specimens examined (Figure 4D and E). Taken together, these findings suggested that 
submicroscopic deletions of the CDKN2b and CDKN2a loci were present in a subset of human 
gastric cancer tissues.  
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Discussion 
Various genetic alterations contribute to the inactivation of tumor-suppressor genes during 
cancer development. We previously demonstrated that H.pylori infection and the resultant 
inflammatory response ectopically induce AID expression in human gastric epithelial cells, 
leading to the generation of somatic mutations in various tumor-related genes such as TP53 13. 
On the other hand, deletion of specific chromosomal loci is another major genetic event that 
inactivates tumor-suppressor genes 34. The molecular processes underlying chromosomal 
deletions, including DSBs and subsequent joining of DNA ends during tumorigenesis, however, 
remain unclear. In the present study, we demonstrated that aberrant AID expression caused 
chromosomal alterations, mainly submicroscopic deletions, at various genetic loci in gastric 
epithelial cells. 
The molecular mechanism underlying AID-dependent chromosomal deletions in gastric 
epithelial cells remains unknown. In the case of the CSR of the Ig gene, which is achieved via 
the generation of DSBs, a nick or gap in the DNA sequence is generated during the repair 
process of AID-initiated C deamination at the preferred sites of the Ig gene. Consequently, AID 
could potentially induce a staggered DSB by generating closely positioned single-strand nicks on 
opposite DNA strands in certain hotspots of the IgH switch regions. DNA lesions intermediate to 
CSR are occasionally misrepaired, leading to chromosomal DSBs, translocations, and deletions 
in B lymphocytes 17. A well-studied case involves the t(8;14)(q24;q32) chromosomal 
translocations that juxtapose the Ig heavy chain (IgH) to the proto-oncogene c-Myc in human 
Burkitt’s lymphomas 35-37. Indeed, several studies have demonstrated the generation of c-myc-Igh 
translocations in the presence of AID in mouse models of developing lymphomas 18, 19, 23. Thus, 
the catalytic activity of AID that is capable of initiating DSBs supports the idea that aberrant 
AID expression in gastric epithelial cells leads to chromosomal aberrations, resulting in 
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submicroscopic deletions at various chromosomal loci. 
The findings of the present study demonstrated that aberrant AID expression preferentially 
caused chromosomal aberrations at the CDKN2b-CDKN2a locus in gastric epithelial cells. 
Chromosomal region 9p21 contains the CDKN2b-CDKN2a locus, which encodes three tumor 
suppressor proteins, p16INK4a, p15INK4b, and p14ARF 29. p16INK4a and p14ARF are potent tumor 
suppressors that regulate the activities of the retinoblastoma protein and the TP53 transcription 
factor 38. Several mechanisms are involved in the inactivation of p16INK4a and p14ARF, including 
chromosomal deletion, somatic mutation, and methylation of CpG islands extending from the 
promoter region to the first exon 39. The deletion at chromosome 9p21 in humans, which 
removes the CDKN2A tumor-suppressor gene, is a genetic alteration frequently observed in 
several human cancers 40, prompting speculation that biochemical pathways regulated by these 
proteins must be disabled for normal cells to be transformed into tumor cells 39. Consistent with 
these findings, we previously demonstrated that AID expression in biliary cells induces somatic 
mutations in the promoter region of the CDKN2A gene 10. Thus, the CDKN2b-CDKN2a locus 
might be a common target for AID-mediated genotoxic effects in both gastric and biliary 
epithelial cells.  
In sharp contrast to the CDKN2b-CDKN2a locus, few of the other genes examined 
exhibited a common susceptibility to AID-mediated genotoxic effects in human and mouse 
gastric epithelial cells. It should be noted that the human CDKN2b-CDKN2a locus is located on 
chromosome band 9p21, while the cognate locus of the mouse genes is present on chromosome 4 
41. The reason for the selective AID attack of the CDKN2b-CDKN2a locus in both humans and 
mice irrespective of the chromosomal region, is not clear. Consistent with the hypothesis that the 
CDKN2A deletion is triggered by AID activity, previous structural analyses of breakpoints for 
CDKN2A deletions in human cancers revealed that DSBs triggering deletions in leukemia cells 
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are formed at a few defined sites by the illegitimate action of the RAG protein complex, while 
DSBs in solid tumors are formed at nonspecific sites in or near the CDKN2a locus by undefined 
factors 40. It was recently demonstrated that AID expression is required to introduce DNA 
single-strand breaks into both rearranged IgH variable-region genes and the CDKN2B gene in 
leukemia cells 42 , and frequent deletion of CDKN2A and CDKN2B was also reported in the 
AID-positive lymphoid blast crisis leukemia cells 43. In support of these findings, we confirmed 
that the upstream sequences of the CDKN2b-CDKN2a locus carries E box motifs (CAGGTG), 
which are tightly associated with AID hypermutation activity at both Ig and non-Ig genes 44, at 
very high density (11 motifs within 10 kbp sequences). Together these findings suggest that there 
are AID-preferential motifs in the sequences around the CDKN2a locus in both human and 
mouse, and thus the genotoxic activity of AID triggers preferential chromosomal deletions as 
well as somatic point mutations in the CDKN2b-CDKN2a locus. 
A number of tumor suppressor genes exhibit epigenetic changes with resulting gene 
silencing in cancers and it is well recognized that the CDKN2A gene is frequently inactivated by 
aberrant methylation32, 45. In contrast, little is known about the genetic changes in the CDKN2A 
and CDKN2B genes in human gastric cancers. Here we demonstrated that copy number losses of 
the CDKN2b- CDKN2a locus were present in a subset of human gastric cancer tissues. We also 
showed that H.pylori infection triggered a reduction in the copy numbers of the Cdkn2a and 
Cdkn2b genes in the gastric mucosa of WT mice, and strikingly, the alterations of the 
Cdkn2b-Cdkn2a gene loci induced by H.pylori infection were not observed in AID-deficient 
mice, indicating an indispensable role of AID in H.pylori-induced genetic alterations of the 
CDKN2b-CDKN2a loci. Because a large population of gastric cancer patients are commonly 
infected with H.pylori and H.pylori potently enhances AID expression in gastric epithelial cells, 
the present data strongly suggest that H.pylori infection triggers inactivation of the CDKN2A and 
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CDKN2B genes through AID-mediated genetic aberrations, contributing to the emergence of 
gastric cancers. 
In conclusion, we demonstrated that aberrant AID expression in gastric epithelial cells 
resulted in the accumulation of submicroscopic deletions in various chromosomal loci. The 
findings that AID preferentially targeted the tumor-suppressor CDKN2b-CDKN2a locus in 
gastric epithelial cells suggest the significance of AID production in gastric cancer development. 
Further analyses are necessary to determine the precise multistep process of genetic alterations in 
human gastric mucosa in association with H.pylori-mediated AID expression. 
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Figure legends  
Figure 1 
Copy number analyses of CDKN2A and CDKN2B genes in AGS cells with or without AID 
activation.  
(A) Copy number profiles on chromosomes 3 and 9 of AGS cells with AID activation for 1 or 3 
weeks, using CGH analyses, are shown. The BCL6 gene is located on chromosome 3, and the 
CDKN2A and CDKN2B genes are located on chromosome 9. Red and green dots represent copy 
number amplification and reduction, respectively. (B) Dual-color FISH analyses for 
AID-expressing AGS cells. Representative images for the CDKN2b-CDKN2a locus (green 
signals) and ELAVL2 gene (red signals) in cells with AID activation for 3 weeks. Chromosomes 
with both CDKN2b-CDKN2a locus and ELAVL2 gene had green and red signals 
(CDKN2b-2a(+)/ELAVL2(+); left panels). Chromosomes without CDKN2b-CDKN2a signals had 
only red signals (CDKN2b-2a(-)/ELAVL2(+); right panels). 
Figure 2 
Copy number analyses of Cdkn2a, Cdkn2b, and Bcl6 genes extracted from gastric epithelial 
cells of 1-year-old WT and AID Tg mice.  
(A) Microscopic images (hematoxylin and eosin stain) of a representative gastric cancer 
developed in a 53-week-old AID Tg mouse (original magnification ×40, upper panel, and 
original magnification ×200, lower panel). Scale bars are 1 mm (upper panel) and 200 µm 
(lower panel). (B, C, D and E) Relative copy number ratio of the Cdkn2a (B), Cdkn2b (C), Bcl6 
(D), and Acot7 (E) genes in the gastric epithelium of the WT and three AID Tg mice, one of 
which developed gastric cancer. Normal gastric mucosa of the WT mouse (WT), non-cancerous 
mucosa of three AID Tg mice (NC), and gastric cancer of the AID Tg mouse (GC) were 
examined. *, P<0.05. **, P<0.01. (F) Southern blot analysis of the Cdkn2a gene in the gastric 
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epithelium of the WT and three AID Tg (Tg#1-3) mice (upper panel) and that of the control Actb 
gene (lower panel).  
Figure 3 
Copy number analyses of Cdkn2a and Cdkn2b genes extracted from gastric epithelial cells 
of WT mice with 2-year H. pylori infection.  
(A and D) AID expression analyses using PCR were performed in gastric epithelial cells with H. 
pylori infection of WT (A; upper panel) or AID-deficient mice (D; upper panel). Control Actb 
expression analyses are shown in lower panels of Figures 4A and D. (B, C, E and F) Relative 
copy number ratio of the Cdkn2a or Cdkn2b genes in gastric epithelium with or without H. pylori 
infection in WT or AID-deficient mice. The data shown represent mean amounts of the Cdkn2a 
or Cdkn2b genes in three WT mice (B and C) or three AID-deficient mice (E and F) with H. 
pylori infection (HP[+]) or the mice without infection (CTR). *, P<0.05. 
Figure 4 
Copy number analyses of CDKN2A and CDKN2B genes extracted from stomach of 28 
patients with gastric cancer. 
(A and B) Relative copy number ratio of the CDKN2A (A) and CDKN2B (B) genes between 
non-tumor and tumor tissues. (C) Southern blot analysis of the CDKN2A gene in non-tumor and 
tumor tissues of 4 representative patients (upper panel) and that of the control ACTB gene (lower 
panel). (D and E) LOH analyses of the CDKN2A (D) and CDKN2B (E) genes in 4 of the 6 
informative patients for which DNA polymorphism analyses were performed. 
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* P < 0.05
** P < 0.01
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Table 1. Frequency of chromosomes with deleted signals identified in AID-expressing AGS cells using CDKN2b-
CDKN2a/ELAVL2 dual-color FISH analyses. 
(42/352) 11.2%ELAVL2








( ) Frequency of the chromosomes without signals Chromosomes without signals/total chromosomes( )Deleted genes
Data represent the frequency of chromosomes with the deletions of targeted genes, and values in parentheses indicate 
number of chromosomes with deleted genes per number of total chromosomes examined. *, P < 0.001, vs. control.







/ total bases( )
CDKN2A 3.01/104 (19/63121) 16/199 * 0.15/104 (1/67726) 1/214
CDKN2B 1.70/104 (11/64842) 11/202 * 0.29/104 (2/68052) 2/212
BCL6 0.46/104 (5/109203) 5/178 0.082/104 (1/121473) 1/198
CDKN2A, CDKN2B and BCL6 sequences were amplified from AGS cells with or without AID activation for 
21 days, followed by analysis of nucleotide sequences in randomly selected clones. Data represent mean 
mutation frequency (left), number of mutated bases per number of total base pairs sequenced (middle, in 







/ total bases( )
Table 3. Mutation frequency of Cdkn2a and Cdkn2b genes in normal gastric mucosa of a 1-year-old wild-type mouse (Control) 
and gastric cancer (GC) and non-cancerous mucosa (NC) of a 1-year-old AID transgenic (Tg) mouse. 
ControlAIDTg(GC) AIDTg(NC)
Cdkn2a 0.89/104 (14/157300) 14/270 * 0.72/104 (11/152347) 11/274 * 0.077/104 (1/130482) 1/319
Cdkn2b 1.55/104 (14/90479) 14/106 * 1.05/104 (10/95186) 10/182 * 0.18/104 (2/112968) 2/216
Cdkn2a and Cdkn2b sequences from mouse gastric mucosa were amplified, followed by analysis of nucleotide sequences in 
randomly selected clones. Data shown in this table are representative and are derived from one control and one AID Tg mouse that 
developed gastric cancer, and represent mean mutation frequency (left), number of mutated bases per number of total base pairs 







/ total bases( ) Mean mutation frequency Mutated clones / total clonesMutated bases / total bases( ) Mean mutation frequency Mutated clones / total clonesMutated bases / total bases( )
Supplementary Figure 1 Matsumoto et al. RT-PCR analyses 
showing the AID expression level in the cell system established by 
stable transformation of AGS cells with the plasmid encoding the
conditionally active form of AID fused with the hormone-binding 
domain of the human estrogen receptor. The expression of AID
(upper panel) and ACTB, encoding β-actin, as an internal control 


























Supplementary Figure 2 Matsumoto et al. Chromosomal profiles of human gastric epithelial AGS cells with AID activation for 21 days 
based on CGH analysis. Ideograms of chromosomes are positioned horizontally and flanked by a copy number plot, which defines 0 






Supplementary Figure 3 Matsumoto et al. Histologic analysis of  
the gastric mucosa of the H.pylori-infected WT C57BL/6 (left panel) 
and AID-deficient (right panel) mice that developed chronic gastritis. 
WT mouse AID-deficient mouse
Supplementary Figure 4 Matsumoto et al. Chromosomal profiles of gastric epithelial cells of WT mouse infected with H.pylori for 2 














































































Supplementary Figure 5 Matsumoto et al. CDKN2A and CDKN2B
mRNA expression in human gastric cancer and surrounding non-
cancerous stomach tissues. Comparison of CDKN2A (A) and 
CDKN2B (B) transcript expression by quantitative real-time RT-
PCR analyses in non-tumor and tumor tissues from the clinical 















































































Primers Sequence (5’ – 3’)




















































Supplementary Table 2 Matsumoto et al. Genes included in the chromosomal loci frequently deleted in AID-
activated human gastric AGS cells.
Deleted loci and genes
















































































IFNB1, W1, A5, A2, A8, E1
MTAP
CDKN2A
CDKN2B
3q25-28;
9p21-23;
3q25-28;
9p21-23;
